Cramer's Morning Take: Eli Lilly & Novo Nordisk 1/24/25

SPEAKER_1 (0:00)

Is it time to reimagine your future? The right business skills may make a difference in your career. At Capella University, we offer a relevant education that's designed to focus on what you need to know in the business world. We'll teach professional skills to help you pursue your goals, like business management, strategic planning, and effective communication, and you can apply these skills right away. A different future is closer than you think with Capella University. Learn more at capella.edu.

SPEAKER_2 (0:31)

This podcast is brought to you by eHarmony, the dating app to find someone you can be yourself with. Authenticity is key in finding a relationship. That's why eHarmony doesn't allow members to copy and paste for their first messages in the app. Your conversations should reflect your uniqueness. So eHarmony is building a community of people who are also putting in the effort. It's 2025 Have conversations that actually help you and your matches get to know each other. Get Who Gets You on eHarmony. Sign up today.

Jim Cramer (1:03)

I'm Jim Cramer and you're about to hear a sample taken directly from today's CNBC Investing Club morning meeting. Boy, do we ever have a lot to cover. Even though we just had our club meeting, there are many things happening. Ten year up a tick, not an oscillator though is a little overboard. So we got to be careful. I lean toward the sell side more than the buy side here today, even though I had a couple of names I talked about yesterday.

I mentioned Capital One, Texas Roadhouse. Can't put anything one number over what like this. But we might be able to do some trimming. But first I want to talk about what's happening with Lilly versus Novo because there's a lot of sense that Lilly's fallen behind Novo and that's not the case.

Jeff Marks (1:39)

No, it's not. Look, Novo Nordisk, they put out a press release today announcing top line results of a phase 1B2A. So very early stage clinical data here of an experimental weight loss drug. Keep in mind, the trial patient size is only 125, so very small, but this is this Amicredin. It's a once weekly subcutaneous drug, but it showed weight loss of 22% on the highest dosage after 36 weeks. And that's really, that's great efficacy. And in some ways it does compare favorably to Lilly's next gen drug, Retachotride, which in a phase two study completed in June, 2023 So again, remember they're very far ahead here, but it showed 20% weight loss roughly over the same time period, 24.2% at 48 weeks. So yes, some people are saying this is best in class for Novo Nordisk and you can see the stock's performance. It really needed any bit of good news it could rally.

Jim Cramer (2:34)

But isn't it interesting that Lilly's up? And I think some of that is what you just talked about. Some of it is the fact that we finally are getting the scripts that you and I were hoping for. Because remember the fourth quarter did not finish well for Lilly. This is a nice pickup.

Jeff Marks (2:45)

Yeah, Wolf mentioned script data today, showed solid high single digit week over week prescription growth. That's kind of what people have been waiting to see for with Eli Lilly. Some other things to keep in mind, the tolerability of Novo Nordisk drug was, they just said it was similar. So you don't know the true data. Right. And then Lilly's also, they have an amylin molecule they're working on as well. So it's not like they're just standing pat. But I think it is the script data, as you mentioned, that is a very encouraging sign to see. Because they were soft towards the end of the year. And we obviously saw those Q4 results.

Jim Cramer (3:23)

Start your day with my outlook on the daily market every morning at 10:20 a.m. Visit cnbc.com/morningtake to access all the benefits of being a CNBC Investing Club member.

SPEAKER_2 (3:38)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC, NBC Universal or their parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Cramer. To view the full CNBC Investing Club Disclaimer, please visit cnbc.com/investingclubdisclaimer.